1. [Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)]
- Author
-
Jacek, Juszczyk, Barbara, Baka-Cwierz, Marek, Beniowski, Hanna, Berak, Beata, Bolewska, Anna, Boroń-Kaczmarska, Janusz, Cianciara, Andrzej, Cieśla, Andrzej, Dziambor, Jacek, Gasiorowski, Andrzej, Gietka, Ewa, Gliwińska, Andrzej, Gładysz, Zbigniew, Gonciarz, Waldemar, Halota, Andrzej, Horban, Małgorzata, Inglot, Urszula, Janas-Skulina, Ewa, Janczewska-Kazek, Jolanta, Jaskowska, Krzysztof, Jurczyk, Brygida, Knysz, Wiesław, Kryczka, Jan, Kuydowicz, Elzbieta A, Lakomy, Beata, Logiewa-Bazger, Anna, Lyczak, Tomasz, Mach, Włodzimierz, Mazur, Zofia, Michalska, Roma, Modrzewska, Khalil, Nazzal, Paweł, Pabjan, Anna, Piekarska, Paweł, Piszko, Katarzyna, Sikorska, Katarzyna, Szamotulska, Magdalena, Sliwińska, Katarzyna, Swietek, Krzysztof, Tomasiewicz, Ewa, Topczewska-Staubach, Hanna, Trocha, Marek, Wasilewski, Marta, Wawrzynowicz-Syczewska, Witold, Wrodycki, Dorota, Zarebska-Michaluk, and Małgorzata, Zejc-Bajsarowicz
- Subjects
Adult ,Male ,Drug Carriers ,Dose-Response Relationship, Drug ,Interferon-alpha ,Hepacivirus ,Hepatitis C, Chronic ,Interferon alpha-2 ,Middle Aged ,Antiviral Agents ,Recombinant Proteins ,Polyethylene Glycols ,Treatment Outcome ,Ribavirin ,Humans ,Drug Therapy, Combination ,Female - Abstract
We evaluated the efficacy and safety of peginterferon alfa-2a [40KD] (Peg-IFNalpha-2a) plus ribavirin in patients with chronic hepatitis C in an open-label programme in a routine clinical setting in Poland. Patients received Peg-IFNalpha-2a 180mg/week plus ribavirin 800-1200 mg/d for 48 weeks. Sustained virological response (SVR) was defined as undetectable HCV RNA (50IU/mL) at the end of follow-up (week 72). 466 adults were enrolled. Most patients (87.3%) had genotype 1 infection. 440 subjects (94,4%) completed treatment. The overall SVR rate was 55.7%. A higher SVR rate was obtained in treatment-naïve patients (58.7%) than in relapsers (47.8%; p=0,048). SVR rates in genotype 1 and non-1 patients were 51.1% and 88.5%, respectively (p0.001). There were significant higher SVR rates in patients with lower baseline fibrosis (p=0,01). There were no differences in SVRs by gender or viral load. Hemoglobin, leukocyte and neutrophil levels decreased significantly during treatment, but returned to baseline after the end of treatment. ALT levels decreased significantly during treatment in patients with and without an SVR. 38.4% of patients experienced adverse events like neutropenia, anemia, thrombocytopenia, and other. There was one death (severe thrombocytopenia).The overall SVR achieved in this predominantly genotype 1 population was 55.7%. SVR rates were significantly higher in treatment-naïve patients, those with non-1 genotypes, and in patients with lower baseline fibrosis scores.
- Published
- 2006